Wealth Effects LLC Sells 225 Shares of Bristol-Myers Squibb (NYSE:BMY)

Wealth Effects LLC decreased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 14,852 shares of the biopharmaceutical company’s stock after selling 225 shares during the period. Wealth Effects LLC’s holdings in Bristol-Myers Squibb were worth $840,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Stonegate Investment Group LLC grew its position in shares of Bristol-Myers Squibb by 1.9% during the 4th quarter. Stonegate Investment Group LLC now owns 27,666 shares of the biopharmaceutical company’s stock worth $1,565,000 after buying an additional 523 shares during the period. Tamar Securities LLC increased its stake in Bristol-Myers Squibb by 1.0% in the fourth quarter. Tamar Securities LLC now owns 418,110 shares of the biopharmaceutical company’s stock valued at $23,648,000 after purchasing an additional 3,950 shares in the last quarter. Perigon Wealth Management LLC raised its holdings in Bristol-Myers Squibb by 23.8% in the fourth quarter. Perigon Wealth Management LLC now owns 60,093 shares of the biopharmaceutical company’s stock worth $3,388,000 after purchasing an additional 11,536 shares during the period. Griffin Asset Management Inc. boosted its position in shares of Bristol-Myers Squibb by 0.7% during the fourth quarter. Griffin Asset Management Inc. now owns 79,614 shares of the biopharmaceutical company’s stock worth $4,503,000 after purchasing an additional 563 shares in the last quarter. Finally, Town & Country Bank & Trust CO dba First Bankers Trust CO increased its position in shares of Bristol-Myers Squibb by 4.0% in the 4th quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 18,375 shares of the biopharmaceutical company’s stock valued at $1,039,000 after buying an additional 700 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Buying and Selling

In other news, EVP Samit Hirawat bought 1,830 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the completion of the transaction, the executive vice president now owns 62,109 shares of the company’s stock, valued at $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Stock Performance

NYSE BMY opened at $60.61 on Tuesday. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.10. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The stock has a 50 day moving average of $57.47 and a 200-day moving average of $52.71.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company had revenue of $11.89 billion for the quarter, compared to analysts’ expectations of $11.26 billion. During the same period in the prior year, the firm earned $2.00 EPS. Bristol-Myers Squibb’s quarterly revenue was up 8.4% compared to the same quarter last year. As a group, equities analysts expect that Bristol-Myers Squibb will post 0.92 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be paid a dividend of $0.62 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a dividend yield of 4.09%. The ex-dividend date of this dividend is Friday, January 3rd. Bristol-Myers Squibb’s payout ratio is currently -69.08%.

Analysts Set New Price Targets

A number of research firms have issued reports on BMY. Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and boosted their target price for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Daiwa America upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 13th. Sanford C. Bernstein initiated coverage on shares of Bristol-Myers Squibb in a report on Thursday, October 17th. They set a “market perform” rating and a $56.00 target price on the stock. UBS Group upped their price target on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, October 9th. Finally, Barclays raised their price objective on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a report on Monday, October 7th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $56.60.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.